To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
133
Erlotinib 150 mg/day (until progression)
Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
Centre Hospitalier - Pneumologie
Belfort, France
APHP - CHU Avicenne - Oncologie Medicale
Bobigny, France
Centre F. Baclesse
Caen, France
CHU - Pneumologie
Caen, France
16-week Disease Control Rate
Time frame: 4-week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CHU Grenoble - pneumologie
Grenoble, France
APHP - Saint-Antoine - pneumologie
Paris, France
APHP - Hopital Tenon - Pneumologie
Paris, France
Institut de Cancérologie de la Loire
Saint-Priest-en-Jarez, France
CHU Lyautey - Pneumologie
Strasbourg, France